ORAL Strategy Efficacy Results
Completed head-to-head non-inferiority study comparing XELJANZ and adalimumab in patients with inadequate response to MTX1
  • XELJANZ + MTX was non-inferior compared with adalimumab + MTX as measured by ACR50 at Month 6*.1
  • XELJANZ monotherapy was not non-inferior compared with adalimumab + MTX or XELJANZ + MTX as measured by ACR50 at Month 6*.1
ORAL Strategy (MTX-IR RA population) – Primary endpoint: ACR50 at Month 6*1
Adapted from Fleischmann R et al. 2017.1​​​​​​​​​​​​​
  • ACR50 response rates were maintained at Month 12.1
ORAL Strategy (MTX-IR RA population) – ACR50 responses over 12 months1
Adapted from Fleischmann R et al. 2017.1​​​​​​​
  • Non-inferiority for the primary endpoint was demonstrated for XELJANZ + MTX vs. adalimumab + MTX*.1
  • Non-inferiority was not demonstrated for XELJANZ vs. adalimumab + MTX or XELJANZ + MTX*.1
Adapted from Fleischmann R et al. 2017.1
Statistical analysis​​​​​​​
  • ​​​​​​The non-inferiority margin was assessed using a 13% difference and non-inferiority was declared if the lower boundary of the 98.34% CI for the difference was larger than -13%.1
  • For any comparison between primary endpoints, if non-inferiority was demonstrated, superiority could be declared if the lower boundary of the 98.34% CI of the difference was greater than zero.1
Explore more​​​​​​​
Dosing in RA
*ACR50 at Month 6 (primary endpoint of the study) was based on the full analysis set.1

ACR, American College of Rheumatology; BID, twice daily; IR, inadequate response; LOCF, last observation carried forward; MTX, methotrexate; NRI, non-responder imputation; Q2W, once every 2 weeks; RA, rheumatoid arthritis; SC, subcutaneous.
1. Fleischmann R et al. Lancet 2017; 390:457–468.
PP-XEL-GBR-3107. Aug 2021
Request an eRep
You can use the email below to contact a product representative and learn more about XELJANZ
[email protected]
XELJANZ Risk Minimisation Programme (RMP) materials, including a Patient Alert Card, Prescriber Checklists and a Prescriber Brochure are available from https://www.medicines.org.uk/emc/. Patients treated with XELJANZ should be given the Patient Alert Card.

© 2021 Pfizer Pte Ltd. All rights reserved.

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.